Altimmune, Inc. (ALT) analyst actions
Rating and price-target actions on ALT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ALT overview →
3 measured ALT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH | Press release | -0.59% | +3.81% | |
| Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) | Press release | +2.83% | +3.27% | |
| Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) | Press release | +0.92% | +0.73% |
Keep exploring
More ALT: earnings → · SEC filings → · ALT overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| GENMARK DIAGNOSTICS (GNMK) | 1,451 | +0.06% | 51% |
| GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) | 1,448 | +0.01% | 51% |
| PerkinElmer, Inc. (PKI) | 1,409 | +0.11% | 56% |
| Zoetis Inc. Class A (ZTS) | 1,406 | +0.02% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.